Pfizer and Germany’s BioNTech announced on Wednesday that they would develop a potential mRNA-based vaccine for the prevention of viral shingles, working together for the third time after the success of their COVID-19 vaccine.
Pfizer partnered with BioNTech in 2018 for an influenza vaccine and again in 2020 to develop the COVID-19 vaccine which has been used around the world and brought in billions of dollars in corporate sales.
Shingles, also known known as herpes zoster, usually develops in older people who had chickenpox or varicella-zoster virus when they were younger.
Written by
This news first appeared on https://techncruncher.blogspot.com/2022/01/pfizer-biontech-to-jointly-develop.html under the title “Pfizer, BioNTech to jointly develop shingles vaccine”. Bolchha Nepal is not responsible or affiliated towards the opinion expressed in this news article.